Imatinib

Generic Name: Imatinib

Brand Names: Gleevec, Glivec, Imatinib Teva, Imatinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₁N_₇O

CAS Number: 152459-95-5

Unique Ingredient Identifier: BKJ8M8G5HI

Background: Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...

Indication: Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor

Associated Therapies: -

Clinical Trials

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Phase 2

Terminated

Conditions: Leukemia

Interventions: Biological: Peptide Vaccine (PR1 Peptide)
Drug: Imatinib
Drug: Peginterferon alfa-2b
Drug: GM-CSF

First Posted Date: 2006-12-25

Last Posted Date: 2018-08-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00415857

Locations: 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States

A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma

Phase 2

Terminated

Conditions: Metastatic Melanoma

First Posted Date: 2006-11-22

Last Posted Date: 2013-12-18

Lead Sponsor: Yale University

Target Recruit Count: 3

Registration Number: NCT00402662

Locations: 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor

First Posted Date: 2006-10-19

Last Posted Date: 2020-07-28

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 35

Registration Number: NCT00390156

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2006-09-14

Last Posted Date: 2014-02-07

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 105

Registration Number: NCT00376467

Locations: 🇮🇹
Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi, Bologna, Italy
🇮🇹
Divisione di Ematologia Ospedale A. Perrino, Brindisi, Italy
🇮🇹
Ospedali Riuniti "Villa Sofia-Cervello", Palermo, Italy

and more 25 locations

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Phase 3

Terminated

Conditions: Leukemia

Interventions: Drug: Dasatinib
Drug: Imatinib

First Posted Date: 2006-08-10

Last Posted Date: 2009-11-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3

Registration Number: NCT00362466

Locations: 🇺🇸
Santee Hematology/Oncology, Sumter, South Carolina, United States
🇺🇸
M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸
Local Institution, Houston, Texas, United States

and more 3 locations